Focused REVIEW

First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization

Andra Fortner¹,*; David Schumacher²,*

¹Albert-Ludwigs-Universität Freiburg, Germany
²Department of Anesthesiology, University Hospital RWTH Aachen, Germany

*Corresponding authors: Andra Fortner, Albert-Ludwigs-Universität Freiburg, Breisacher Straße 153, 79110 Freiburg, Germany, Email: af415@mars.uni-freiburg.de; David Schumacher, Department of Anesthesiology, University Hospital RWTH Aachen, Germany, Email: dschumacher@ukaachen.de

Submitted: January 15, 2021; Revised: February 25, 2021; Accepted: February 25, 2021; Published: March 05, 2021; Citation: Fortner A, Schumacher D. First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization. Discoveries 2021, 9(1): e122. DOI: 10.15190/d.2021.1

ABSTRACT
On December 31, 2019, the Wuhan Municipal Health Commission reported an increase in the incidence of pneumonia from an unknown cause. Shortly after, SARS-CoV-19 was identified as the responsible coronavirus for the heavy progress of the disease, which can manifest itself distinctly in different individuals. Coronavirus Disease 2019 (COVID-19) triggered a pandemic because of its high contagiousness before COVID-19 associated symptoms actually appear. In response to the rapid and continuous spread of the virus around the globe governments have mobilized their forces to restrict contact and thus avoid further infection and invested significant resources in treatment and prevention strategies to tackle COVID-19. As a result, US FDA and EMA have granted emergency use authorization for two mRNA-based vaccines, namely the vaccines developed by BioNTech/Pfizer and Moderna, for use in the USA and Europe. Due to the existing critical situation, the stages of vaccine development and testing have probably never been gone through so fast as at present. Here, we are briefly commenting on these two vaccines with their benefits, advantages and limitations.

Keywords
COVID-19, vaccine, mRNA vaccine, US Food and Drug Administration, European Medicines Agency.

ABBREVIATIONS
Coronavirus Disease 2019 (COVID-19); U.S. Food and Drug Administration (FDA); European Medicines Agency (EMA); Lipid nanoparticles (LNPs).

1. Introduction

Public interest in mRNA vaccines has arisen greatly since the global pandemic of COVID-19. As of February 20, 2021, more than 2,435,000 people have died from or with COVID-19 all over the world and more than 109,900,000 have been infected¹. Although there are more than 50 vaccines in clinical trials and more than 240 in pre-clinical development³⁴⁵, only two vaccines have been authorized for emergency use by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) until January 2021, these vaccines, therefore, being in the center of attention to contribute to the halt of the uncontrollable spread of the pandemic (Table 1).

Both vaccines are based on a new mRNA technology as their active agent, and therefore, take a new approach to vaccination. Unlike traditional forms of vaccinations that use inactivated, live-attenuated or a sole antigen of a virus, new vaccination methods are currently being researched. Apart from mRNA-based vaccines, those methods include DNA-based vaccines, viral vectors or the injection of antigen-presenting cells³.
First COVID-19 Vaccines approved for emergency use in USA and Europe

While the first approved mRNA-based vaccine in Europe and USA named BNT162b2, which is also known under the name Comirnaty, has been developed by the German company BioNTech in collaboration with the USA company Pfizer, the other vaccine, mRNA-1273 COVID-19, was developed in Cambridge, MA, USA4-9 (Figure 1, Table 1).

2. Vaccines approved for emergency use by US FDA and EMA

The first vaccine receiving emergency authorization by the FDA on December 11, 20206, and by the EMA on December 21, 20207, is the mRNA-based vaccine Comirnaty from Pfizer and BioNTech. Shortly after, the FDA and the EMA granted Moderna’s vaccine access on the market on December 18, 20208, and January 06, 2020 respectively9 (Figure 1).

Both vaccines contain a mRNA single-strand coding for the spike protein10,11 of the SARS-CoV-2. This type of protein can be found on the virus’ surface and it is known to allow the coronavirus to enter the host cells12,13. The mRNA itself is made up of a 5’ cap, UTR sequences before and after the actual coding sequence and a poly(A) tail at the 3’ end of the single strand. These structures provide the molecule stability in the cytoplasm and promote the process of translation14. Furthermore, the two vaccines are nucleoside-modified, meaning that some single RNA nucleotides have been exchanged in order to create codons coding for the same amino acid. These new codons, however, are more efficiently translated because their corresponding tRNA molecule can be found in greater amounts inside the cell.

Another important component of the vaccines are lipid nanoparticles (LNPs) enclosing the mRNA. Their function refers to the in vivo delivery of the mRNA: on the one hand, LNPs prevent the nucleic acid from being degraded by RNAses in the extracellular space and on the other hand, they aid the uptake of the mRNA into cells at the injection site15. The two FDA and EMA authorized vaccines are very similar but structurally differ in the type of lipid used for the lipid nanoparticles16.

Once the mRNA has been released in the cytoplasm of the target cell, it will pass through the process of translation, creating the SARS-CoV-19 spike protein’s peptide chain that will be properly folded in further steps. The mRNA strand itself is broken down after translation. Body cells display antigens on special cell receptors (MHC) on the cell surface, where they can be recognized by human immune cells. This generates a humoral and cell-mediated immune response by activating different types of antigen-specific lymphocytes (B and T cells). B-cells produce high amounts of antibodies that can bind the epitopes of the vaccinated antigen.
in order to neutralize it, whereas cytotoxic T-cells specifically kill body cells presenting the antigen on their MHC receptors. The remaining antibodies and immune cells continue to circulate through the body. They are the basis for immunity against SARS-CoV-19[10,11].
In the case of a secondary infection, the virus can quickly be recognized and is neutralized at the epitopes of its spike protein by antibodies. At the same time, cytotoxic T-cells specifically spot infected body cells and kill them to prevent the spreading of the SARS-CoV-19 infection inside the body. Hence, the virus is destroyed and the onset of COVID-19 disease symptoms can be prevented.

Both vaccines - BNT162b2 and mRNA-1273 - are administered two times. The second injection of the vaccine should mimic a secondary infection by inducing new production of the antigen and serves as a booster to obtain a greater immunity against SARS-CoV-19. According to the vaccination schedule the second dose of BNT162b2 is given after 21 days, whereas mRNA-1273 is readministered after 28 days. The two vaccines also differ as BNT162b2 has to be diluted prior to use.

Several other vaccines are now evaluated/approved by the FDA and EMA, including the Janssen’s COVID-19 vaccine (AD26.COV2-S) developed by the Janssen Pharmaceutical Companies (Johnson & Johnson) and their partners (such as Beth Israel Deaconess Medical Center, Boston, USA), approved for emergency use by FDA on February 28, 2021 and AZD 1222 developed by the University of Oxford with AstraZeneca and their partners (see Table 1). On January 29, 2021, EMA has recommended granting a conditional authorization for AZD 1222 vaccine use in Europe.

There are many advantages, benefits, but also limitations for the mRNA vaccines, which are discussed in the next section.

3. Advantages and Limitations

Similar to any other studied immunogenic substances and approaches, there are aspects that play in favour of or against the usage of mRNA vaccines.

3.1 Efficacy

Until now, both vaccines have been shown to be highly effective. Clinical trials of BioNTech/Pfizer and Moderna suggest that both vaccines prevent COVID-19 more or less equally well (95%, respectively 94.1% efficacy). Both trials were conducted randomized, placebo-controlled and observer-blinded. A total of 43,448 volunteers participated in the clinical trial of BioNTech/Pfizer, whereas Moderna’s clinical trial counted a smaller number of individuals (30,420). In each study, the number of participants has been divided in half; one group being injected with the mRNA-based vaccine, while the other group was given a placebo. All test subjects have been tested for SARS-CoV-19 infection after receiving the second dose of vaccine, respectively placebo: seven days after the second administration in BioNTech/Pfizer’s study and 14 days after the second administration in Moderna’s study. 162 infected people have been confirmed in the placebo group and only 8 people in the BNT162b2 group. These numbers have been calculated to an efficacy of 95%. In the other trial there have been 185 infections in the placebo group and only 11 in the group receiving Moderna’s mRNA vaccine, resulting in an efficacy of 94.1%.

Both test results reveal that the vaccines’ efficacy is not influenced by age, gender, ethnicity or pre-existing illnesses of individuals.

In comparison to the conventional way of injecting the antigen only, mRNA vaccines may provide a stronger type of immunity because not only antibodies are built in a humoral immune response, but also specific killer cells come into action.

However, many new variants of the SARS-CoV-19 have evolved recently. This presents a challenge due to the possibility of increased contagiousness of new SARS-CoV-19 variants that can develop because of random mutations in the virus’ genome. Some examples are the B.1.1.7 variant, first observed in the UK; variant B.1.351, discovered in South Africa or variant B.1.1.28 P.1, first found in Brazil. Questions are raised on whether the two mRNA-based vaccines or the other vaccines are able to generate immunity efficiently against mutated SARS-CoV-2 virus, because the spike protein’s structure of the mutated virus might too greatly differ from the spike protein encoded by the vaccines. Further research into this area is required.

3.2 Safety

Although it is true that many of the exact biological processes of the respective substances and immunity are not fully understood, it is important to note that research into this type of vaccine has already started years ago and the vaccines have continuously been improved since then. Additionally, clinical trials
First COVID-19 Vaccines approved for emergency use in USA and Europe

Table 2. Pfizer and Moderna vaccines
Information adapted with permission from⁴,¹⁹,²¹,²²

| Name                          | COMIRNATY concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) | COVID-19 Vaccine Moderna dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) |
|-------------------------------|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| **Age indication**            | 16 years old and older                                                                       | 18 years old and older                                                                       |
| **Vaccination schedule**      | 2nd dose after 21 days                                                                       | 2nd dose after 28 days                                                                       |
| **Dosage**                    | 30 micrograms of COVID-19 mRNA Vaccine (embedded in lipid nanoparticles)                     | 100 micrograms of messenger RNA (mRNA) (embedded in SM-102 lipid nanoparticles)             |
| **Administration**            | intramuscularly                                                                              | intramuscularly                                                                              |
| **Efficacy**                  | ~ 95%                                                                                       | ~ 94.1%                                                                                    |
| **Undesired/adverse effects in the clinical trial(s)** | pain at the injection site pain (> 80%), fatigue (> 60%), headache (> 50%), myalgia and chills (> 30%), arthralgia (> 20%), pyrexia and injection site swelling (> 10%). | pain at the injection site (92%), fatigue (70%), headache (64.7%), myalgia (61.5%), arthralgia (46.4%), chills (45.4%), nausea/vomiting (23%), axillary swelling/tenderness (19.8%), fever (15.5%), injection site swelling (14.7%), redness (10%). |
| **Storage**                   | Unopened vial: 6 months at -90 °C to -60 °C, up to 5 days at 2 °C to 8 °C, protected from light. | Unopened vial: 7 months at -25°C to -15°C, 30 days at 2°C to 8°C, up to 12 hours at 8°C to 25°C, protected from light. |
|                               | After dilution: 6 hours at 2 °C to 30 °C.                                                    | Punctured Vial: 6 hours at 2°C to 25°C.                                                     |
| **Vials**                     | 2 mL clear multidose vial. Each vial contains 5 doses of 0,3mL. Pack size: 195 vials.        | 5 ml dispersion in a vial. Each vial contains 10 doses of 0.5mL. Pack size: 10 multidose vials. |
| **Excipients**                | ((4-hydroxybutyl)azanediy|l|bis(hexane-6,1-diy|l|bis(2-hexyldecanoate) (ALC-0315), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159), 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), Cholesterol, Potassium chloride, Potassium dihydrogen phosphate, Sodium chloride, Disodium phosphate dihydrate Sucrose, Water for injections. | Lipid SM-102, Cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000 DMG), Tromethanol, Tromethanol hydrochloride, Acetic acid, Sodium acetate trihydrate, Sucrose, Water for injections. |

have been and are still being conducted in order to determine whether vaccines can meet the standards set by the responsible institutions⁵⁶. Since the vaccine is based on mRNA, the vaccine itself is not infectious and concerns on the genetic piece being inserted into our DNA-genome are unfounded⁴. In addition, mRNA has an only short halflife in the cytoplasm as it is degraded by enzymes after translation⁴. Despite this, and especially as all organisms respond differently to the same substance, adverse effects can still occur.
because of unintended immune reactions to the mRNA strand\textsuperscript{27}.

Regarding the reactogenicity of the two FDA and EMA authorized vaccines, adverse effects in the clinical trials were usually mild or moderate in intensity and resolved after vaccine is administered in few days\textsuperscript{21,22}, whereby these effects generally occured more often in younger people and after the second dose of vaccine\textsuperscript{21-22}. Side effects include pain at the injection site, fatigue, headache, muscle pain, joint pain and chills (see Table 2) and indicate that an immune response is generated\textsuperscript{19-22}.

However, because of the recentness of the usage of mRNA-based vaccines, possible long-term effects as well as the duration of immunity are still difficult to assess\textsuperscript{19}. Therefore, they will play an important role in the future development of mRNA vaccines and a stringent monitoring is required in present time. Another unanswered question is whether people who have already been vaccinated and thus don’t develop the symptoms of COVID-19 can nevertheless spread the virus to other people\textsuperscript{19}. Furthermore, studies have not yet looked enough into potential side effects of the two authorized mRNA vaccines on pregnant women\textsuperscript{21,22}.

Many stories reporting the death of individuals after receiving vaccination have been spread over the media. Although such stories sound very deterrent and alarming, no causal link could be identified between the reported deaths and the vaccination. One example of a study conducted to investigate the death of patients shortly after receiving mRNA-based COVID-19 vaccination is the report of the Paul Ehrlich Institute in Germany, that assessed 113 reported deaths occurring between one hour and 19 days after vaccination. Firstly, it could be observed that all patients had pre-existing or previous illnesses. Thus, their death could more likely be explained by other factors than the vaccine itself. Maybe the synergy of both might have been the problem. Secondly, 20 patients died of COVID-19 disease. It could be seen that all those people except one man had only received the first dose of vaccination\textsuperscript{26,29}. This shows the importance of completing the vaccination schedule in order to achieve protection from COVID-19 disease.

3.3 Production time and standardization

In contrast to some of the traditional vaccines, infectious parts of the pathogen are not part of the vaccine, but only the instruction to build such a part is. Therefore, the time needed for the multiplication, growth and inactivation or isolation of the wanted part of the virus can be saved. This traditional process also consumes a lot of material, namely the tissue the viruses are grown on (chicken or mammalian eggs)\textsuperscript{27}. On the contrary, once the genetic sequence of the antigen is known, the mRNA-based vaccine can easily be recreated in biomedical laboratories all over the world\textsuperscript{15,26,27}. Hence, mRNA vaccine manufacturing is not only less time-consuming but also cheaper, as laboratories are usually equipped with the required materials\textsuperscript{27}. This also facilitates large-scale vaccine production, which is particularly important in regard to reducing the impact of pandemics\textsuperscript{27}.

3.4 Storage

On the downside, mRNA-based vaccines have to be stored and transported at very low temperatures which is an obstacle for their distribution to the people. For example, Comirnaty must be kept at -90°C to -60°C, whereas Moderna vaccine can resist at slightly higher temperatures (-25°C to -15°C). These vaccines are only valid a few months (Comirnaty 6 months and Moderna vaccine 7 months). Thus, vaccine distribution has to be logistically well organized to ensure that the produced vaccines can actually reach their recipients. Once the vials have been opened, again time remaining for consumption is very little (see Table 2)\textsuperscript{21,22}.

3.5 Versatility

When comparing mRNA vaccines to conventional vaccination methods (Table 3), however, a huge advantage is the possibility of modeling the mRNA and thus changing its action mechanisms inside the organism\textsuperscript{14}.

Changing the molecular structure of the mRNA can yield a different rate of translation or in-vivo half-life. Purification of the mRNA further contributes to this and can also decrease immunogenicity inside the organism\textsuperscript{14}. Another important aspect is complexing of the mRNA in different carriers to achieve a better delivery of the active agent into target cells\textsuperscript{14}.

mRNA vaccines are highly adaptive. As mRNA is made up of the same basic building units in all organisms, a new vaccine can easily be produced by just changing the sequence of the four nucleotides to code for a pathogen-specific antigen. The only
First COVID-19 Vaccines approved for emergency use in USA and Europe

The actual sequence coding for the antigen. This feature makes mRNA vaccines so valuable to quickly respond to outbreaks of infectious diseases, such as the actual COVID-19 pandemic. Moreover, its therapeutic use in treating cancer is also being studied. Here, the mRNA can code for a tumour-specific antigen and can thus teach the body’s immune system to actively fight cancer cells.

4. Conclusion

Although COVID-19 still presents a challenge, worldwide disease prevention is making great progress thanks to the rapid development, testing and authorization of vaccines. There are many different and innovative approaches to achieve immunity, and so far, two mRNA-based vaccines have been proven to be highly effective in their clinical testing phases. Once it has reached the cell, the mRNA uses the cellular translation machinery to be expressed as the SARS-CoV-2 antigen. The body can recognize the produced protein as pathogenic and an immune response is stimulated, teaching the body’s immune cells how the critical part of SARS-CoV-2 looks like, to be able to defend the body against it. Indeed, side effects occur quite often, but in most cases, they are attributable to the generated immune response and can thus indicate that the vaccine is actually working. Nevertheless, long term effects, possible effects on pregnant women and whether the vaccines prevent their recipients from

Table 3. Advantages and limitations of mRNA-based vaccines and traditional vaccines

| VACCINE TYPE                  | ADVANTAGES                                                                 | DISADVANTAGES/LIMITATIONS                                                                 |
|-------------------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Existing mRNA-based vaccines  | + Efficacy: both vaccines have been shown to offer good protection from COVID-19 disease; + stronger type of immunity is provided; + safety: short in vivo half-life of the mRNA strand decreases the probability of possible side effects; + adverse effects are usually only mild; + design and production is faster and potentially cheaper since it uses less resources, although it is more expensive to distribute (special storage required); + large-scale production is possible; + mRNA strand can be adapted to fight various diseases, not only infections. | - potential side effects, especially long-term ones still have to be investigated; - efficacy against new variants is yet unknown; - still unclear, whether vaccinated individuals can infect others; - storage requires very low temperatures; - relatively short shelf life; - two vaccine shots needed. |
| Traditional vaccines          | + potent vaccine; + proven technology; + may not require adjuvants; + single injection often generates efficient immunity. | - manufacturing: relatively expensive, time-consuming, requires a lot of materials; - higher risk of infection during manufacturing; - difficult to scale up production. |
being contagious still have to be investigated and more research is required. Therefore, it is important that even people who have been vaccinated follow the rules of hygiene, maintaining a distance of 1.5 meters from others, wearing a mask in order to decrease the risk of spreading the virus.

As for the mRNA vaccines in general, they have the potential to be a very adaptive and potent instrument in reducing infections by creating immunity inside the vaccinated organisms. It is possible to modulate the aggressiveness, efficacy and other features of the vaccine by using molecular engineering techniques. Moreover, mRNA-based vaccines can be produced relatively fast, in great amounts and in a standardized fashion to fight any type of antigen the mRNA is coding for. Thus, they represent a promising tool in preventing future epidemics and pandemics and even cancer therapy. Yet, the low temperatures required for mRNA-vaccine storage remain a problem as they impede vaccine distribution. Overall, it is important to constantly re-evaluate the vaccines by carefully monitoring their consumption.

Personally, we think that the emergency authorization of the two mRNA-based vaccines is a promising step forward that can challenge and overcome the actual COVID-19 pandemic. However, there is still a lot more work to be performed.

Acknowledgements
DS was supported by the Clinician Scientist program of the Faculty of Medicine of the RWTH Aachen University. AF thanks to the Albert-Ludwigs-Universität Freiburg for support.
AF designed, organized the review, searched, analyzed and summarized the data and wrote the manuscript. DS supervised the work and contributed to the manuscript writing.

Conflict of Interest
The authors declare no conflicts of interest.

References
1. WHO Coronavirus Disease (COVID-19) Dashboard. 2021 Accessed: 2021 February 20. Available from: https://covid19.who.int/
2. Milken Institute COVID-19 Vaccine Tracker. Accessed: 2021 February 20. Available from: https://www.covid-19vaccinetracker.org/#Top-of-Page
3. van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat. Mater. 2020;19: 810–812.
4. Die Corona-Impfstoffe von Biontech und Moderna im Vergleich. Accessed: 2021 January 7. Available from: https://rp-online.de/panorama/coronavirus/corona-impfstoff-biontech-und-moderna-kostenwirkung-nebenwirkungen_aid-55550063
5. Milken Institute COVID-19 Vaccine Tracker: Vaccines in Use. Accessed: 2021 February 20. covid-19vaccinetracker.org/authorized-vaccines
6. U.S. Food & Drug Administration: Pfizer-BioNTech COVID-19 Vaccine. Accessed: 2021 January 12. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine
7. European Medicines Agency: Comirnaty. Accessed: 2021 January 12. Available from: https://www.ema.europa.eu/en/medicine/human/EPAR/comirnaty
8. U.S. Food & Drug Administration: Moderna COVID-19 Vaccine. Accessed: 2021 January 12. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine
9. European Medicines Agency: COVID-19 Vaccine Moderna. Accessed: 2021 January 12. https://www.ema.europa.eu/en/medicine/human/summaries-opinion/covid-19-vaccine-moderna
10. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. New England J Med. 2020;383(20):1920-31.
11. BioNTech BNT162 COVID-19 Vaccine: Update on Clinical Development Program. April 2020. Accessed: 2021 January 12. Available from: https://www.pei.de/SharedDocs/Downloads/EN/newsroom-en/dossiers/ppt-erste-studie-sars-cov-2-impfstoff-en.pdf?__blob=publicationFile&v=2
12. Elie CR. COVID-19 therapy and prevention. Discoveries 2020, 8(3): e113. DOI: 10.15190/d.2020.10
13. Saha O, Rakhi NN, Sultana A, Rahman MM, Rahaman MM. SARS-CoV-2 and COVID-19: A Threat to Global Health. Discoveries Reports 2020; 3: e13. DOI: 10.15190/drep.2020.7
14. Pardi, N., Hogan, M., Porter, F. et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 2018;17: 261-279.

15. Anthony Komaroff, MD: Why are mRNA vaccines so exciting? On December 10, 2020 in Coronavirus and COVID-19, Health Vaccines. Accessed: 2021 January 12. Available from: https://www.health.harvard.edu/blog/why-are-mrna-vaccines-so-exciting-2020121021599

16. Eric Levenson and Jacqueline Howard, CNN: What we know about Moderna's coronavirus vaccine and how it differs from Pfizer's. Updated 2058 GMT (0458 HKT) December 20, 2020 Accessed: 2021 January 12. Available from: https://edition.cnn.com/2020/12/17/health/moderna-vaccine-what-we-know/index.html

17. Zhu S, Guo X, Geary K, Zhang D. Emerging Therapeutic Strategies for COVID-19 patients. Discoveries 2020, January-March; 8(1); e105. DOI:10.15190/d.2020.2

18. BioNTech: mRNA vaccines to address the COVID-19 pandemic. Accessed: 2021 January 12. Available from: https://biontech.de/covid-19-portal/mrna-vaccines

19. Branswell H. A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines. DECEMBER 19, 2020. Accessed: 2021 January 12. Available from: https://www.statnews.com/2020/12/19/a-side-by-side-comparison-of-the-pfizer-biontech-and-moderna-vaccines/

20. Towhid ST, Rakhi NN, Arefin ASMS, Saha O, Mamun S, Moniruzzaman M, Rahaman MM. COVID-19 and the Cardiovascular System: How the First Post-Modern Pandemic ‘Weakened’ our Hearts. Discoveries Reports, 2020; 3: e15. DOI: 10.15190/drep.2020.9

21. Comirnaty: Product information. Accessed: 2021 January 12. Available from: https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf

22. Product Information as approved by the CHMP on 6 January 2021, pending endorsement by the European Commission. Accessed: 2021 January 12. Available from: https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-moderna-product-information_en.pdf

23. Bade LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384:403-416.

24. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383:2603-2615.

25. Coronavirus-Mutation: Was Sie wissen sollten. Accessed: 2021 February 20; Available from: https://www.apotheke-umschau.de/Coronavirus/Coronavirus-Mutation-Was-Sie-wissen-sollten-562163.html

26. Centers for Disease Control and Prevention: Understanding mRNA COVID-19 Vaccines. Updated Dec. 18, 2020. Accessed: 2021 January 12. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html

27. Laura Blackburn: RNA vaccines: an introduction. October 2018. Accessed: 2021 January 12. https://www.phgfoundation.org/briefing/rna-vaccines

28. Verdachtsfälle von Nebenwirkungen und Impfkomplikationen nach Impfung zum Schutz vor COVID-19. Accessed: 2021 February 20; https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/sicherheitsberichte/sicherheitsbericht-27-12-bis-31-01-21.pdf?__blob=publicationFile&v=5

29. Fact check: No links found between vaccination and deaths. Accessed: 2021 February 20; Available from: https://www.dw.com/en/fact-check-are-covid-19-vaccines-causing-deaths/a-56458746

This article is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes; 2021, Former A. et al., Applied Systems and Discoveries Journals.